I’m excited about the Neurometrix prospects (Nasdaq:NURO). They are trading at 50 cents and a market cap of 11 million. Well below their cash position of 15 million. NC Stat Medicare reimbursement issues are the reason why they got hit so hard. One of their major investors, James Flynn, selling it with somewhat a disregard of price is the reason it is down to this level. The whole time their president, Shai Gozani, has been buying which shows belief in the company. James Flynn is almost out and a new product, DPNCheck, which goes around the problems of NC Stat reimbursement is coming out at the American Diabetes Association conference next week. It’s at price point low enough for the average American with diabetes to check for a more serious issue before they would more seriously chance loosing a limb. The tests on the market right now are only used once more serious issues like foot ulcers are seen. At that point it could already be too late. DPNCheck will be the only product of its kind and is coming out next week. It could havethe hype that the NC stat had taking NURO to the 30 dollar range a few years back. I think it has been written off as of late but will have a huge catalyst starting next week. Do the research but there are not too many opportunities like this around, insider buying, under cash, and a new growth product that is one of a kind. There has been reason why its down this low but that reason is about to end.